Home › Immune System and Disorders › Pennsylvania › Pittsburgh
Immune System and Disorders clinical trials in Pittsburgh, PA
4 studies for Immune System and Disorders are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- West Penn Hospital, Pittsburgh
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
RecruitingObservational study
- UPMC Hillman Cancer Center, Pittsburgh
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- UPMC Hilman Cancer Center, Pittsburgh
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
About Immune System and Disorders
Your immune system is made up of cells, tissues, and organs that fight infections and diseases. Learn how it works, and about diseases of the immune system.
More about Immune System and Disorders on MedlinePlus
Immune System and Disorders trials in other cities
- Washington, DC13 studies
- New York City, NY12 studies
- Boston, MA10 studies
- Philadelphia, PA10 studies
- Portland, OR9 studies
- Atlanta, GA9 studies
- Houston, TX9 studies
- Cleveland, OH8 studies
- Los Angeles, CA8 studies
- Chicago, IL8 studies
- Milwaukee, WI6 studies
- Seattle, WA6 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Lung Cancer23 studies
- Prostate Cancer23 studies
- Stroke22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.